Reviewer's report

Title: Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

Version: 1 Date: 11 November 2013

Reviewer: José Manuel Olivares

Reviewer's report:

The use of Clinical Guidelines in clinical practice has an increasing interest among clinicians, particularly in helping to provide guidance in specific clinical situations not well addressed in randomized clinical trials (due to a number of well-known methodological reasons). In a world of Medicine based on Evidence, some Evidence based on Medicine is welcome, even though it may lack the high-level evidence provided by randomized clinical trials or meta-analysis.

In this particular manuscript, the task of providing a Guideline for the use and management of long-acting injectable antipsychotics in serious mental illness is pretty well addressed, the methods are well described and appropriate, and the discussion and conclusions are well balanced.

I would recommend the paper to be published as it is.

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

In the last five years I have been involved in advisory/consultancy boards organized by Astra-Zeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Otsuka and Sanofi-Aventis, and I have been the recipient of honoraria (as a researcher and/or lecturer) from Janssen-Cilag, Lundbeck, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Sanofi-Aventis and Pfizer.

I do not hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this paper, either now or in the future.

I do not hold any patent relating to the content of the manuscript.

I do not have any other financial and/or non-financial competing interests in relation to this paper.